secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001140361-25-002125
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics elects all 11 director nominees, ratifies auditor at 2024 annual meeting
--------------------------------------------------------------------------------

- All 11 director nominees elected with votes for ranging from 18.2M to 19.0M; broker non-votes of 20.0M.
- Ratification of Cherry Bekaert LLP as auditor: 38.7M for, 162.8K against, 408.9K abstain.
- Annual meeting held January 23, 2025; directors elected for term until next annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125002125/0001140361-25-002125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125002125/ef20042347_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-002125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer